197,666 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Walleye Capital LLC

Walleye Capital LLC purchased a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 197,666 shares of the company's stock, valued at approximately $3,129,000. Walleye Capital LLC owned 0.49% of Keros Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Clearbridge Investments LLC bought a new stake in Keros Therapeutics in the fourth quarter valued at $3,009,000. JPMorgan Chase & Co. increased its position in shares of Keros Therapeutics by 585.9% during the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock valued at $3,379,000 after buying an additional 182,314 shares during the period. Federated Hermes Inc. bought a new position in Keros Therapeutics in the fourth quarter worth about $1,973,000. Vanguard Group Inc. lifted its holdings in Keros Therapeutics by 5.4% in the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after buying an additional 100,691 shares during the period. Finally, Emerald Advisers LLC boosted its position in Keros Therapeutics by 57.3% during the 4th quarter. Emerald Advisers LLC now owns 244,633 shares of the company's stock valued at $3,873,000 after acquiring an additional 89,088 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KROS shares. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Wedbush restated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a report on Tuesday, April 1st. Truist Financial lowered their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Finally, Scotiabank cut their price target on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.33.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 22.90% of the company's stock.

Keros Therapeutics Price Performance

Keros Therapeutics stock traded up $0.30 during mid-day trading on Wednesday, reaching $14.19. 317,962 shares of the stock traded hands, compared to its average volume of 1,376,453. The stock has a market capitalization of $575.57 million, a PE ratio of -2.72 and a beta of 1.39. The business's 50-day moving average is $11.33 and its 200-day moving average is $28.60. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.